Medical Cannabis: Clinical, Formulation, & Regulatory Considerations
Cannabis has multiple pharmacologically active components capable of producing a wide range of clinical effects in humans. With growing evidence of the potential therapeutic benefits of cannabis, healthcare professionals must carefully consider all aspects of cannabis-based treatment, including formulation factors and potential interactions.
In this webinar, the relationship between cannabis and the human body in terms of pharmacokinetics, pharmacodynamics, and physiology will be reviewed. Consideration for different dosage forms and routes of administration available, dosing and titration to minimize adverse events and achieve treatment goals, and drug interactions of cannabis with other commonly prescribed medications will also be examined. Finally, this webinar will discuss the legal framework within which the prescription and use of cannabis is woven, with focus on American, Canadian, an Australian regulatory status.
- Pharmacy Technicians
- Nurse Practitioners
- Discuss the endocannabinoid system, cannabinoid pharmacology, cannabinoid products, and common formulations.
- Examine the beneficial and harmful effects associated with cannabinoid use, including its effect on the lungs, gastrointestinal system and skin, its adverse events, and drug interactions.
- Design a role for the pharmacist related to medical cannabis for patient counseling in various settings, such as in self-titrating during dosing.
- Explore the legal jurisprudence surrounding use of recreational and medicinal cannabis in the United States, Canada, and Australia.
The webinar is copyright © 2019 LP3 Network.
High speed internet connectivity and an updated internet browser is required to attend the webinar. The broadband recommended is 1 Mbps or better. The minimum browser requirements to attend the webinar are:
- Google Chrome v39 or later
- Mozilla Firefox v34 or later
- Internet Explorer v8 or later
- Microsoft Edge
- Apple Safari v6 or later
|CHRISTINE ROUSSEL, PharmD, BCOP|
Assistant Director of Pharmacy, Doylestown Hospital
Christine Roussel is a board certified oncology pharmacist and the Assistant Director of Pharmacy at Doylestown Hospital in Pennsylvania where she is responsible for clinical program development and compounding activities. Dr. Roussel also serves as adjunct professor at the University of the Sciences in Philadelphia. Dr. Roussel is an expert in hazardous compounding and has served as the Cancer Center Pharmacy Manager at the Einstein Healthcare System where she was instrumental in directing the design and clinical workflow processes and protocols for the dedicated on-site oncology pharmacy facility. As well, she managed the planning, building and maintenance of the sterile hazardous drug compounding facility. Dr. Roussel also established an outpatient specialty pharmacy service line for cancer center patients, providing clinical and copay-assistance guidance to patients. In her previous role as the Vice President of Pharmacy Operations for the OncoMed Oncology Pharmacy of Philadelphia, a closed door specialty pharmacy, Dr. Roussel oversaw training of all clinical staff on treatment guidelines, patient counseling, regulatory requirements, compounding techniques, and the safe handling of hazardous chemotherapy agents. Dr. Roussel oversaw the maintenance of the cleanroom facilities and wrote the company’s policies and procedures for their sterile compounding program.
Dr. Roussel received her Bachelor of Science in Toxicology and her Doctorate in Pharmacy from the Philadelphia College of Pharmacy at the University of the Sciences and is currently an active member of the American Society of Health System Pharmacists (ASHP), the American Pharmacist Association (APhA), and the Hematology Oncology Pharmacists Association (HOPA). Dr. Roussel is also an active member of the Legislative Action Committee for the Pennsylvania Society of Health Systems Pharmacy.
CANCELLATION AND REFUND POLICY:
There are no refunds, returns or transfer upon purchase of the webinar.